A review discussing the therapeutic potentials of NK cell biology has been published in the journal Frontiers of Medicine.

Glycostem is opening new horizons in allogeneic NK-cell-based immunotherapy, thanks in large part to its cutting-edge platform technology. In recent years, Glycostem’s platform technology has ...

Anti-KIR blocking antibodies has led to important therapeutic implications in NK cell immunotherapy. 1-7F9 is a human monoclonal antibody that cross reacts with KIR2DL-1, -2, -3 and prevents their ...

Alloreactive NK cells can be delivered either as adoptive immunotherapy or within the context of hematopoietic cell transplantation (HCT). There are three methods from which NK cell products for ...

FATE-NK100 – Fate’s most advanced immuno-oncology product is FATE-NK100, a first-in-class cancer immunotherapy that uses programmed donor NK cells to treat patients. NK cells have an innate ...

Natural killer (NK) cells play an important role in the innate immune response to cancer and viral infections, and their ...

As technical hurdles are overcome, these innovative treatments are poised to revolutionize cancer immunotherapy. Studying the basics of natural killer (NK) cells, where they come from, and how ...

“We connect NK cells with tumor cells so they can destroy ... Innate Pharma’s therapies mark the dawn of a new generation of immunotherapy agents. “For the last 10 years, I think ...

Potentiating therapeutic mAb-mediated CD16 activation of NK cells is an emerging area for cancer immunotherapy. CAR-NK cells with multi-specific molecules composed of stabilized CD16 and/or other ...

Severe infection with Covid-19 has been found to produce a powerful cancer-fighting cell that can shrink tumors.

Dendritic cells are poised to revolutionize oncology. This type of immune therapy shows effectiveness even in late-stage ...

T cell-based immunotherapies including immune checkpoint blockade and chimeric antigen receptor T cells can induce durable responses in patients with cancer. However, clinical efficacy is limited due ...